We first established that exogenous IGF1 treatment induced the exhibition of cancer stemness, including increased side-population (SP) and ALDH1 activity, accompanied by the increased resistance against the chemotherapeutic agent, 5-FU, and enhanced tumor-initiating ability in vivo. Here, ALDH1A1 is linked to cancer.